The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
Myasthenia Gravis Foundation of America
355 Lexington Ave 15th Floor
New York, NY 10017-6603
The Myasthenia Gravis Foundation of America (MGFA) is a national, non-profit agency whose mission is to facilitate the timely diagnosis and optimal care of individuals affected by myasthenia gravis and closely related disorders and to improve their lives through programs of patient services, public information, medical research, professional education, advocacy and patient care. Myasthenia gravis is a rare autoimmune disease affecting the neuromuscular junction and producing weakness of voluntary muscles. The foundation produced a quarterly newsletter, brochures, newsletters, pamphlets, a Survival Guide, information cards and manuals for nurses and physicians. Founded in 1952, the Myasthenia Gravis Foundation has more than 36 chapters and 100 support groups.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and that credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions are strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.